Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
FREMONT, Calif. - Tivic Health Systems, Inc. (NASDAQ:TIVC), a micro-cap biotech currently trading at $3.98, announced that shareholders have approved key proposals necessary for the company’s strategic transformation during its annual meeting held on June 30, 2025. According to InvestingPro analysis, the stock appears slightly undervalued based on its Fair Value metrics.
The approved proposals include the issuance of equity as payment for Tivic’s worldwide exclusive license agreement for Entolimod and Entolasta, which are being developed for acute radiation syndrome, neutropenia, and other oncology and hematology indications. Shareholders also approved equity issuance related to previously announced financing arrangements, both of which required approval under Nasdaq listing rules. InvestingPro data shows the company maintains a healthy current ratio of 1.7, though it faces significant challenges with a -54.5% revenue decline over the last twelve months.
"We have established a strong foundation for Tivic’s expansion into biopharmaceutical markets," said Jennifer Ernst, Tivic’s CEO, in the press release. Ernst noted that the company has received "strong customer interest" in Entolimod’s potential applications for acute radiation syndrome and secured exclusive rights for its use in treating neutropenia, which the company claims is a market projected to reach nearly $21 billion worldwide by 2032.
The company also announced leadership changes, with Lisa Wolf assuming the permanent Chief Financial Officer role after serving as Interim CFO for nine months. Additionally, Blake Gurfein is stepping down as Chief Scientific Officer after eight years but will continue supporting the company’s Vagus Nerve Stimulation program as a consultant. InvestingPro analysis indicates the company faces significant operational challenges, with a weak Financial Health Score of 1.67 and negative gross profit margins of -22.29%.
Tivic Health describes itself as a diversified immunotherapeutics company developing biochemical and bioelectric therapies. Its lead product candidate Entolimod has received Fast Track and Orphan Drug designation from the FDA for acute radiation syndrome treatment. The company’s first FDA-approved product, ClearUP, is designed to treat sinus pain and pressure. With a market capitalization of just $3.5 million and a beta of 2.0, investors should note that InvestingPro identifies this as a highly volatile stock. Get access to the full TIVC research report and 8 additional ProTips with an InvestingPro subscription.
The information in this article is based on a press release statement from Tivic Health Systems.
In other recent news, Tivic Health Systems Inc. reported a significant decline in its first-quarter 2025 revenue, dropping 79% to $70,000 compared to the previous year. Despite the revenue fall, gross margins improved from 50% to 72%, largely due to cost-cutting measures, including a reduction in advertising expenses by 92%. The company is in the midst of a strategic transformation, focusing on biopharmaceutical asset development, particularly with the acquisition of rights to the drug candidate Entelimod. Shareholders have approved key proposals for the issuance of equity related to this license agreement and other financing arrangements, which are crucial for Tivic’s expansion into biopharmaceutical markets.
Additionally, Tivic Health announced leadership changes, with Lisa Wolf taking on the permanent role of Chief Financial Officer and Blake Gurfein transitioning to a consultant role. The company also set new deadlines for stockholder proposals for its 2025 Annual Meeting, emphasizing compliance with Rule 14a-8 and other regulatory requirements. Tivic Health has secured a strategic financing agreement, which includes an $8.4 million tranche to support its transformation efforts. The company is optimistic about future developments, with plans to file a Biological Licensing Application and achieve key milestones later in the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.